Duchenne Muscular Dystrophy: Second Product Isn't The Charm

 
• By Derrick Gingery

FDA reviewers say patients treated with Sarepta's eteplirsen seemed to follow similar disease course as Duchenne muscular dystrophy natural history, casting doubts on product's approvability.

More from United States

More from North America